SHELTON, Conn., April 18, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") announced today that it has been recognized as one of the "Most Innovative Business Leaders of 2016" by AI Global Media, publisher of Acquisition International Magazine and Website ("AI") (http://www.acquisition-intl.com).
A focus article on NanoViricides was published in AI Magazine, February 2016 issue.
"A nanoviricide® is a nanomedicine designed to neutralize and potentially destroy the virus. We had a chance to catch up with representatives from the Company and learn how they are leading the way with their advancements in this demanding field," state the editors. The article then recites from an interview with Dr. Anil R. Diwan, President of NanoViricides, Inc.
"NanoViricides, Inc. is a unique company in the bio/pharma field with the potential to become a stand-alone pharmaceutical company. We now have a fully customizable c-GMP-capable pilot manufacturing plant where we can produce multi-kilogram quantities of any nanoviricide, including injectables. This enables rapid translation of our drug candidates into human clinical trials. Early revenues upon drug approval will also be possible with our own manufacturing capability," said Dr. Diwan, regarding the positioning of NanoViricides in the pharma space.
"We believe that we will be transitioning our drug candidates into clinical stage in the very near future. Our pipeline is very broad and rich. So we will be able to advance a number of drugs into clinical trials, one after another, in the near future, limited only by the available finances. We believe that the chances of clinical success of our drug candidates are very high. Thus we anticipate advancing a number of highly effective and safe antiviral drugs in the market, in a sustained manner. With our advanced R&D, we believe that we will remain an innovative and dynamic company, with continuing commercialization even after the first drug goes to market, for a very long time into the future. While we believe we will be able to grow organically to become a successful stand alone pharma company, we plan to seek commercialization options like licensing, joint ventures, and others to improve speed to market, in order to speed up revenue," explained Dr. Diwan, about the future and the strategy of the Company.
The entire AI article on NanoViricides is now available on the NanoViricides website (www.nanoviricides.com).
AI is a monthly magazine that seeks to inform, entertain, influence, and shape the global corporate conversation through a combination of high quality editorial, rigorous research and an experienced and dedicated worldwide network of advisors, experts and contributors. Launched over five years ago, AI has rapidly risen to become the publication of choice for more than 108,000 subscribers in over 170 countries and regularly attracts editorial submissions from some of the biggest players on the global corporate landscape, including KPMG, EY, PwC and Deloitte. Alongside the monthly publication, AI Global Media also produces a website that is updated daily with the latest news, features, opinion and comment, again in conjunction with a host of top-level advisors, experts and businesspeople. The site is also home to the popular Deal Diary, which publishes, every day, more than 100 deals in a wide variety of sectors and industries, and a dedicated weekly deal round-up, giving the people behind the most significant M&A activity a global platform to shout about their most recent successes.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
SOURCE NanoViricides, Inc.